Skip to content

NRXPW

NRX Pharmaceuticals, Inc.

NASDAQ · Healthcare · Biotechnology · US

$0.01
+0.00%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
-0.3%
EBIT
+2.1%
EPS
+38.9%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
—
EBITDA
-15.7%
EBIT
+17.7%
Net income
-13.9%
EPS
+43.9%
Free cash flow
-32.7%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026